The Unmet Needs for Identifying the Ideal Bowel Preparation
Overview
Affiliations
Colonoscopy, since it was first employed over 60 years ago, is now the gold standard method for visualizing the mucosa of the colon, but should be of good quality. Many factors affect quality, including the type of health service organization, type of facility, staff, equipment, patient characteristics, and bowel preparation (BP). The adequacy of bowel cleansing is critical, but, unfortunately, may be inadequate in up to one-third of procedures. The current article will present and discuss the main BPs and their drawbacks, which include patient-dependent and procedure-dependent factors. Cleansing quality depends on the ease/complexity of solution preparation, volume, taste, and timing of consumption. Consequently, important positive factors include simple instructions, easy preparation of the solution, low volume, pleasant taste, short drinking time (e.g. <30 min), and splitting the dose between the evening before and the morning of the colonoscopy (or even better, only one dose in the early morning to avoid night-time problems), and short onset of action. The BP solution must also be safe with negligible side effects. Furthermore, a positive experience supports patient willingness to repeat the procedure.
Pasquale L, Grande G, Zagari R, Biancheri P, Pisani A, Da Massa Carrara P Endosc Int Open. 2025; 13:a25158539.
PMID: 40007647 PMC: 11855237. DOI: 10.1055/a-2515-8539.
Effectiveness of a Mobile Health Application for Educating Outpatients about Bowel Preparation.
Chen H, Tu M, Chen M Healthcare (Basel). 2024; 12(14).
PMID: 39057517 PMC: 11275862. DOI: 10.3390/healthcare12141374.
Pharmacokinetics of oral mannitol for bowel preparation for colonoscopy.
Fiori G, Spada C, Soru P, Tontini G, Bravi I, Cesana B Clin Transl Sci. 2023; 15(10):2448-2457.
PMID: 37074807 PMC: 9579383. DOI: 10.1111/cts.13373.
Gao Y, Lin X Turk J Gastroenterol. 2022; 34(1):26-34.
PMID: 36511605 PMC: 9984965. DOI: 10.5152/tjg.2022.22033.
Oral mannitol for bowel preparation: a dose-finding phase II study.
Spada C, Fiori G, Uebel P, Tontini G, Cesaro P, Grazioli L Eur J Clin Pharmacol. 2022; 78(12):1991-2002.
PMID: 36287232 PMC: 9649514. DOI: 10.1007/s00228-022-03405-z.